Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies DOI Creative Commons
Mary Hollist,

Abraham Hollist,

Katherine Au

et al.

Neuroscience Insights, Journal Year: 2024, Volume and Issue: 19

Published: Jan. 1, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, emerged in December 2019, sparking global health crisis. While initially recognized as illness, it has become evident that Coronavirus disease 2019 (COVID-19) also affects the central nervous system. This comprehensive review focuses on neurological manifestations of COVID-19 and its impact patients with preexisting disorders, particularly those multiple sclerosis (MS) receiving disease-modifying therapies. Advancements management, including vaccinations, antiviral therapy, targeted prophylaxis, have led to decline incidence severity COVID-19. Nevertheless, significant complications persist, advanced MS, who are highly vulnerable infectious agents like SARS-CoV-2. explores evolving understanding MS association SARS-CoV-2, encompassing neuroinvasiveness, pathogenesis, severity, outcomes. Research findings reveal substantial implications for some COVID-19, potential risk relapse severity. A notable proportion experiencing may manifest new symptoms, experience exacerbation existing or encounter both simultaneously, underscoring diverse effects virus. vaccination therapeutics mitigated overall impact, specific subgroups, especially anti-CD20 therapy disability, remain at higher risk, necessitating ongoing vigilance tailored care.

Language: Английский

Effects of COVID‐19 vaccination during pregnancy on SARS‐CoV‐2 infection and maternal and neonatal outcomes: A systematic review and meta‐analysis DOI
Masoud Rahmati, Dong Keon Yon, Seung Won Lee

et al.

Reviews in Medical Virology, Journal Year: 2023, Volume and Issue: 33(3)

Published: March 10, 2023

SARS-CoV-2 infection during pregnancy is associated with adverse maternal and neonatal outcomes, but no systematic synthesis of evidence on COVID-19 vaccination against these outcomes has been undertaken. Thus, we aimed to assess the collective effects outcomes. PubMed/MEDLINE, CENTRAL, EMBASE were systematically searched for articles published up 1 November 2022. A review meta-analysis performed calculate pooled size 95% confidence interval (CI). We evaluated 30 studies involving 862,272 individuals (308,428 vaccinated 553,844 unvaccinated). Overall analyses in pregnant women showed reduced risks by 60% (41%-73%), hospitalisation 53% (31%-69%), intensive care unit (ICU) admission 82% (12%-99%). Neonates 1.78 folds more likely acquire first 2, 4 6 months life Omicron period. The risk stillbirth was 45% (17%-63%) association (vs. vaccination) pregnancy. decrease 15% (3%-25%), 33% (14%-48%), (17%-46%) odds preterm births before 37, 32 28 weeks' gestation pregnancy, respectively. ICU significantly lower 20% following (16%-24%). There a higher including miscarriage, gestational diabetes, hypertension, cardiac problems, oligohydramnios, polyhydramnios, unassisted vaginal delivery, cesarean postpartum haemorrhage, age at placental abruption, Apgar score 5 min below 7, low birthweight (<2500 g), very (<1500 small age, foetal abnormalities. safe highly effective preventing without increasing reduction stillbirth, births, admission. Importantly, did not reduce

Language: Английский

Citations

45
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis DOI Creative Commons

Shaymaa Glhoom,

Aya Fergany,

Dina El-Araby

et al.

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: Jan. 5, 2024

Abstract Background During the COVID-19 pandemic, some populations, including immunocompromised patients, could not tolerate vaccination or had low responses. Evusheld is a combined neutralizing monoclonal antibody containing tixagevimab and cilgavimab. The World Health Organization (WHO) has approved this combination as pre-exposure prophylaxis (PrEP) treatment for patients. With new variant, recommended an increase in dose from 300 to 600 mg with booster after 6 months. target of review was compare efficacy two doses, tixagevimab/cilgavimab (Evusheld) higher-risk individuals reveal if there significant difference between those doses drug. Methods In study, electronic databases (PubMed, Web Science core collection, Scopus, Cochran) were investigated articles up 31/12/2022 English using well-established search strategy. We included studies conducted patients (aged ≥ 12 years) received COVID-19. After excluding inconsistent selection criteria, 24 involved, 22 which meta-analysis. analyzed data by RevMan 5.4 program software. Results double-arm subgroup analysis, mg, administered prophylaxis, showed no infection rate, mortality needed hospitalization rate compared ( p = 0.13, 0.29, 0.25, respectively). single-arm decrease 0.0001, 0.007, As treatment, over placebo group 0.01) Conclusion This result indicated that effective prophylactic therapeutic drug infection, especially but considerable variation high doses. Further prospective randomized controlled trials (RCTs) increased population sizes are necessary show valuable benefit prevention within adverse events.

Language: Английский

Citations

9
Future of the current anticoronaviral agents: A viewpoint on the validation for the next COVIDs and pandemics DOI Open Access
Amgad M. Rabie

Biocell, Journal Year: 2023, Volume and Issue: 47(10), P. 2133 - 2139

Published: Jan. 1, 2023

Despite the global decline in severity of coronavirus disease 2019 (COVID-19) cases, still represents a major concern to relevant scientific and medical communities. The primary drug scientists, virologists, other concerned specialists this respect is find ready-to-use suitable potent anticoronaviral therapies that are broadly effective against different species/strains coronaviruses general, not only current previous (e.g., recently-appeared severe acute respiratory syndrome 2 "SARS-CoV-2"), i.e., antiviral agents for treatment and/or prophylaxis any coronaviral infections, including those coming ones from next species strains (if any). As an expert field, I tried, up-to-date perspective "viewpoint" article, evaluate suitability applicability using currently-available diseases (COVIDs) pandemics, highlighting most important general guidelines should be considered pandemics therapeutic points view.

Language: Английский

Citations

16
Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression DOI Creative Commons
Andree Kurniawan, Timotius Ivan Hariyanto

Narra J, Journal Year: 2023, Volume and Issue: 3(1), P. e102 - e102

Published: April 28, 2023

It is important to identify risk factors for poor outcomes of coronavirus disease 2019 (COVID-19) patients. Currently, the correlation between non-alcoholic fatty liver (NAFLD) and COVID-19 has not been established. This study was conducted determine association NAFLD in-hospital The systematic searches were by using PubMed Europe PMC databases particular keywords used as December 10, 2020. Further up 2022. All articles that include data about collected. Statistical analysis performed Review Manager 5.4 Comprehensive Meta-Analysis version 3 software. A total 7,210 patients from 18 studies included in final analysis. Meta-analysis revealed increased developing outcome (pooled both severe death) (RR 1.42; 95%CI: 1.17–1.73, p<0.001, I2=84%, random-effect modeling). Subgroup however found having only chance getting 1.67; 1.32–2.13, I2=86%, modeling) mortality 1.00; 0.68–1.47, p=0.98, I2=80%, Meta-regression suggested age (p=0.001) diabetes (p=0.029) significantly influenced relationship mortality). weaker with median ≥45 years old 1.29) when compared <45 2.96). In addition, prevalence ≥25% had a <25% 1.85). conclusion, therefore it should be evaluated closely reduce COVID-19.

Language: Английский

Citations

13
Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future DOI Creative Commons

David A. Van Eijndhoven,

Robin Vos, Saskia Bos

et al.

Transplant International, Journal Year: 2025, Volume and Issue: 38

Published: Feb. 10, 2025

Coronavirus disease 2019 (COVID-19) has significantly impacted lung transplant recipients (LTR), who remain vulnerable to severe COVID-19 despite vaccination, prompting the use of monoclonal antibodies (mAbs) as a treatment option. This systematic review summarizes clinical efficacy mAbs against in adult LTR and provides perspective on role for infectious diseases future. A search PubMed/MEDLINE, Embase Cochrane was conducted studies reporting outcomes or solid organ (SOTR) including with drug-specific outcomes. Twelve were included. Pre-exposure prophylaxis reduced breakthrough infection LTR. Early correlated incidence outcomes, although statistical significance varied among studies. Overall, observational have demonstrated potential benefit LTR, both early treatment, well importance administration. Moreover, mAb therapy appeared safe could be viable option other pathogens, route that warrants further investigation. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=382133 , identifier CRD42022382133.

Language: Английский

Citations

0
Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies DOI Creative Commons
G. Olivieri, Donato Amodio, Emma Concetta Manno

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 51, P. 126853 - 126853

Published: Feb. 12, 2025

Language: Английский

Citations

0
The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: A systematic review and meta-analysis DOI Creative Commons
Chao‐Hsien Chen, Cheng‐Yi Wang, Ching-Yi Chen

et al.

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(1), P. e0295366 - e0295366

Published: Jan. 19, 2024

The influence of inhaled corticosteroids (ICS) on COVID-19 outcomes remains uncertain. To address this, we conducted a systematic review and meta-analysis, analyzing 30 studies, to investigate the impact ICS patients with COVID-19. Our study focused various outcomes, including mortality risk, hospitalization, admission intensive care unit (ICU), mechanical ventilation (MV) utilization, length hospital stay. Additionally, subgroup analysis assess effect chronic obstructive pulmonary disease (COPD) asthma. findings suggest that prior use did not lead significant differences in ICU admission, or MV utilization between individuals who had used previously those not. However, COPD, was associated lower risk compared non-users (OR, 0.95; 95% CI, 0.90–1.00). Overall, while significantly affect general, it may have beneficial effects specifically for COPD. Nevertheless, more research is needed establish definitive conclusion role treatment. PROSPERO registration number: CRD42021279429 .

Language: Английский

Citations

3
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies DOI Creative Commons
Francesco Angotzi, Marco Petrella, Tamara Berno

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: June 22, 2023

The approved combination of Tixagevimab/Cilgavimab has been shown to decrease the rate symptomatic SARS-CoV-2 infection in patients at increased risk inadequate response vaccination. However, was tested a few studies that included with hematological malignancies, even if this population an unfavorable outcomes following (with high rates hospitalization, intensive care unit admission, and mortality) poor significant immunization vaccines. We performed real-life prospective cohort study evaluate pre-exposure prophylaxis anti-spike seronegative compared seropositive who were observed or received fourth vaccine dose. recruited 103 mean age 67 years: 35 (34%) followed from March 17, 2022, until November 15, 2022. After median follow-up 4.24 months, 3-month cumulative incidence 20% versus 12% observation/vaccine groups respectively (HR 1.57; 95% CI: 0.65-3.56; p = 0.34). In study, we report our experience tailored approach prevention malignancies during omicron surge.

Language: Английский

Citations

7
Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study DOI Creative Commons
Irit Nachtigall,

Stefan Kwast,

Sven Hohenstein

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 634 - 634

Published: June 7, 2024

Aims: Endemic SARS-CoV-2 infections still burden the healthcare system and represent a considerable threat to vulnerable patient cohorts, in particular immunocompromised (IC) patients. This study aimed analyze in-hospital outcome of IC patients with severe infection Germany. Methods: retrospective, observational study, analyzed administrative data from inpatient cases (n = 146,324) 84 German Helios hospitals between 1 January 2022 31 December regard health care during first 12 months Omicron dominance. As primary objective, outcomes COVID-19-related acute respiratory (SARI) were by comparing 2037) without diagnoses 14,772). Secondary analyses conducted on SARI 129,515). A as composite endpoint was defined per WHO definition if one following criteria met: intensive unit (ICU) treatment, mechanical ventilation (MV), or death. Results: In total, 12% COVID-related patients, accounting for 15% ICU admissions, MV use, 16% deaths, resulting higher prevalence courses developing compared non-IC (Odds Ratio, OR 1.4, p < 0.001), based mortality (OR increased need treatment 1.3, 0.001) 1.2, 0.001). Among profoundly risk 4.0, Conclusions: Our findings highlight vulnerability COVID-19. The persistently high these era emphasizes necessity continuous assessment monitoring

Language: Английский

Citations

2
Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis DOI Creative Commons
Saeed Khorramnia, Zia Navidi, Amirhossein Orandi

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 38(2), P. 136 - 144

Published: June 21, 2024

Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs). This study was performed to assess the effectiveness of Tix/Cil for preexposure prophylaxis COVID-19 this population.

Language: Английский

Citations

2